Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | PDE9A | O76083 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19008170 | 0.91 | MAP4K4 (0.44) | MAP4K4KCNH2CXCR4CYP2D6 | |
| SCHEMBL18626520 | 0.86 | MAP4K4 (0.39) | HRH3MAP4K4PDE9AALDH1A1LMNA | |
| SCHEMBL19016231 | 0.82 | MAP4K4 (0.46) | HRH3MAP4K4KCNH2LMNASMN1; SMN2 | |
| SCHEMBL12090335 | 0.80 | MAP4K4 (0.45) | HRH3MAP4K4KCNH2CYP2D6 | |
| SCHEMBL17896399 | 0.76 | HRH3 (0.44) | HRH3MAP4K4KCNH2LMNANPSR1 | |
| SCHEMBL17896402 | 0.76 | MAP4K4 (0.47) | HRH3MAP4K4 | |
| SCHEMBL2603279 | 0.75 | HRH3 (0.59) | HRH3KCNH2LMNACYP2D6 | |
| SCHEMBL17896405 | 0.75 | CHRM2 (0.49) | HRH3MAP4K4KCNH2 | |
| SCHEMBL13162857 | 0.74 | HRH3 (0.47) | HRH3MAP4K4 | |
| SCHEMBL25103813 | 0.74 | HRH3 (0.39) | HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9592235-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-9382241-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | DPYD, FANCD2, RECQL | HRH3 400/4885MAP4K4 700/4885PDE9A 3326/4885 |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | HRH3 408/4885MAP4K4 662/4885PDE9A 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.